Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $736.7 million.

  • Madrigal Pharmaceuticals' Total Liabilities rose 14880.11% to $736.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $736.7 million, marking a year-over-year increase of 14880.11%. This contributed to the annual value of $287.9 million for FY2024, which is 2238.39% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Total Liabilities is $736.7 million, which was up 14880.11% from $319.4 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Total Liabilities' 5-year high stood at $736.7 million during Q3 2025, with a 5-year trough of $49.2 million in Q1 2021.
  • For the 5-year period, Madrigal Pharmaceuticals' Total Liabilities averaged around $211.0 million, with its median value being $199.0 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 2197.18% in 2024, then soared by 14880.11% in 2025.
  • Madrigal Pharmaceuticals' Total Liabilities (Quarter) stood at $77.2 million in 2021, then skyrocketed by 113.9% to $165.2 million in 2022, then skyrocketed by 42.4% to $235.2 million in 2023, then rose by 22.38% to $287.9 million in 2024, then skyrocketed by 155.93% to $736.7 million in 2025.
  • Its Total Liabilities was $736.7 million in Q3 2025, compared to $319.4 million in Q2 2025 and $286.0 million in Q1 2025.